Responses
Clinical and epidemiological research
Extended report
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
Compose a Response to This Article
Other responses
No responses have been published for this article.